Market Closed -
Nasdaq
21:00:00 10/05/2024 BST
|
5-day change
|
1st Jan Change
|
2.85
USD
|
+1.06%
|
|
+9.62%
|
-32.14%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
27.69
|
29.5
|
18
|
5.082
|
2.835
|
5.772
|
-
|
-
|
Enterprise Value (EV)
1 |
27.69
|
29.5
|
18
|
5.082
|
2.835
|
5.772
|
5.772
|
5.772
|
P/E ratio
|
-1.53
x
|
-0.84
x
|
-0.15
x
|
-0.29
x
|
-0.09
x
|
-1.58
x
|
-1.84
x
|
-1.27
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
0.63
|
0.72
|
2.97
|
41.5
|
675
|
2,025
|
-
|
-
|
Reference price
2 |
43,680
|
40,740
|
6,069
|
122.6
|
4.200
|
2.850
|
2.850
|
2.850
|
Announcement Date
|
30/03/20
|
31/03/21
|
31/03/22
|
20/03/23
|
29/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-14.74
|
-26.43
|
-59.06
|
-12.68
|
-15.77
|
-21.26
|
-31.42
|
-52.57
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-15.18
|
-32.67
|
-58.54
|
-14.63
|
-15.79
|
-21.26
|
-31.42
|
-52.57
|
Net income
1 |
-15.18
|
-41.73
|
-84.52
|
-14.63
|
-16.1
|
-21.26
|
-31.42
|
-52.57
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-28,560
|
-48,300
|
-39,774
|
-420.0
|
-47.88
|
-1.800
|
-1.550
|
-2.250
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
30/03/20
|
31/03/21
|
31/03/22
|
20/03/23
|
29/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-30.4
|
-11.17
|
-9.382
|
-5.406
|
4.39
|
-2.28
|
-4.062
|
-4.182
|
-3.433
|
-4.094
|
-4.135
|
-4.763
|
-5.625
|
-6.736
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-30.4
|
-11.17
|
-9.627
|
-5.408
|
4.391
|
-3.986
|
-4.071
|
-4.189
|
-3.434
|
-4.101
|
-4.135
|
-4.763
|
-5.625
|
-6.736
|
Net income
1 |
-30.52
|
-11.29
|
-10.31
|
-5.553
|
4.234
|
-3.986
|
-4.158
|
-4.284
|
-3.483
|
-4.178
|
-4.135
|
-4.763
|
-5.625
|
-6.736
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-13,734
|
714.0
|
-2,772
|
-1,050
|
364.0
|
-189.4
|
-36.40
|
-37.80
|
-9.200
|
-44.71
|
-2.430
|
-0.3200
|
-0.3700
|
-0.4300
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
15/11/21
|
31/03/22
|
23/05/22
|
15/08/22
|
14/11/22
|
20/03/23
|
12/05/23
|
14/08/23
|
13/11/23
|
29/03/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
30/03/20
|
31/03/21
|
31/03/22
|
20/03/23
|
29/03/24
|
-
|
-
|
-
|
Last Close Price
2.85
USD Average target price
36
USD Spread / Average Target +1,163.16% Consensus |
1st Jan change
|
Capi.
|
---|
| -32.14% | 5.77M | | +17.96% | 44.96B | | +1.17% | 42.65B | | +48.77% | 41.85B | | -4.27% | 29.04B | | +11.42% | 26.08B | | -21.39% | 19.03B | | +4.86% | 12.75B | | +27.29% | 12.06B | | -3.50% | 11.75B |
Other Biotechnology & Medical Research
|